Aditxt, Inc., a biotech company listed on The Nasdaq Capital Market under the symbol 'ADTX', has filed a prospectus with the SEC detailing a common stock purchase agreement with Seven Knots, LLC. The agreement, dated May 2, 2024, allows for the sale of up to $150 million of Aditxt's common stock to Seven Knots at Aditxt's discretion. As of the prospectus date, no shares have been sold under this agreement. The last reported sale price of Aditxt's common stock was $0.496 per share as of September 10, 2024. The agreement is part of Aditxt's strategy to secure funding for its operations and growth initiatives, which include developing a portfolio of health innovations. The company's approach involves securing, growing, and monetizing innovations...Show More

Aditxt, Inc., a biotech company listed on The Nasdaq Capital Market under the symbol 'ADTX', has filed a prospectus with the SEC detailing a common stock purchase agreement with Seven Knots, LLC. The agreement, dated May 2, 2024, allows for the sale of up to $150 million of Aditxt's common stock to Seven Knots at Aditxt's discretion. As of the prospectus date, no shares have been sold under this agreement. The last reported sale price of Aditxt's common stock was $0.496 per share as of September 10, 2024. The agreement is part of Aditxt's strategy to secure funding for its operations and growth initiatives, which include developing a portfolio of health innovations. The company's approach involves securing, growing, and monetizing innovations through a systemized process, with a focus on immune health, precision health, population health, women's health, and neurologic health. Aditxt's growth strategy includes expanding its infrastructure and securing more health innovations that align with personalized and precision medicine. The company has also entered into several agreements, including a clinical trial agreement with Mayo Clinic and licensing agreements with Loma Linda University and Stanford University, among others. Aditxt has also engaged in M&A activities, such as the planned acquisition of Appili Therapeutics Inc. and a merger with Evofem Biosciences, Inc. The company has faced financial challenges, including the need to address a lease default notice and the issuance of senior notes to raise funds. The prospectus also outlines the risks associated with investing in Aditxt's securities, including market volatility and potential dilution of existing shareholders.